Table 1 Cases with Miller Fisher Syndrome after COVID-19 vaccination
Age | Sex | Nationality | Type of Vaccine | Number of vaccinations | Time from vaccine to onset (days) | Past history | Neurological findings | CSF cells(/ul) and Protein (mg/dl) | Anti-ganglioside antibodies | NCS | Treatment | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
30 | M | Japan | Pfizer BNT162b2 | 2 | 7 | none | bilateral gaze palsy, areflexia, ataxia | 1 / 30.8 | GQ1b, GT1a | normal | IVIg | recovered | [15] |
71 | M | Japan | Pfizer BNT162b2 | 2 | 16 | DM | ptosis, loss of light reflex, oculomoter nerve palsy, ataxia | 1 / 67 | negative | normal | IVIg | recovered | [16] |
24 | F | N.R. | Pfizer BNT162b2 | 1 | 18 | none | impaired abduction and elevation of both eyes | 2 / 296 (albmin) (mg/L) | GQ1b | normal | IVIg | recovered | [17] |
37 | M | Syrian | Pfizer BNT162b2 | 1 | 9 | none | dysphagia, dysarthria | N.R. | N.R. | N.R. | IVIg | N.R. | [18] |
72 | M | Japan | COVID-19 Moderna | 2 | 7 | HT, HL, HUA, AR | diplopia, ataxia | N.D. | GQ1b | F-wave abnormalities | IVIg | recovered | our case |